The Biostatistics and Patient Registry Core provides statistical collaboration and data management support for each of the SPORE projects, the Cores, the Developmental Research Projects and the Career Development Awardees. Areas of support include development of a statistical design and analysis plan, quality control, database development, data form development and processing, data collection and entry, data analysis and interpretation, manuscript preparation, and data archiving. The Biostatistics and Patient Registry Core will continue to oversee the development, population, and maintenance of the Breast Cancer Patient Registry (BCPR). Members of the Biostatistics and Patient Registry Core will continue collaborations with the Mayo Foundation staff who are working on an enterprise-wide initiative to develop a virtual data warehouse that integrates elements of the Mayo electronic medical record. Surgical Index, Pathology index. Tumor Registry, Tissue Registry, Cancer Center database, orders, and resource utilization database. These collaborations will lead to a means to identify patient cohorts for Breast Cancer SPORE projects and to electronically populate some elements into the BCPR. During the previous funding period, the Core has employed and adapted the time-tested procedures and systems developed by Division of Biomedical Statistics and Informatics, one of the largest statistical groups in the country. The Breast Cancer Patient Registry (BCPR) grew from a single study database containing demographic and outcome data to a database capable of storing data on a variety of patient cohorts using both common data elements and study specific data elements. Not only has the BCPR data been utilized by SPORE investigators but pre-defined patient cohorts have been shared with the DCIS Collaborative Consortium, Breast Cancer Association Consortium, the Consortium of Investigators of Modifiers of BRCAI/2, and The Cancer Genome Atlas. Core members have participated in Project meetings as well as have held one on one meetings with Project team members to discuss statistical designs, analysis plans, emerging research questions and possible future directions;data analysis and interpretation, and the drafting of manuscripts. These collaborations have led to 29 publications that have contributed to our understanding of breast cancer development, risk and management.

Public Health Relevance

The Core provides SPORE investigators with access to individuals with expertise in statistical design;analysis techniques;and data management as well as access to a means to identify patient cohorts and obtain consistently collected and verified data for these cohorts.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA116201-09
Application #
8757106
Study Section
Special Emphasis Panel (ZCA1-RPRB-7)
Project Start
Project End
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
9
Fiscal Year
2014
Total Cost
$329,696
Indirect Cost
$83,403
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Augusto, Bianca; Kasting, Monica L; Couch, Fergus J et al. (2018) Current Approaches to Cancer Genetic Counseling Services for Spanish-Speaking Patients. J Immigr Minor Health :
Supekar, Nitin T; Lakshminarayanan, Vani; Capicciotti, Chantelle J et al. (2018) Synthesis and Immunological Evaluation of a Multicomponent Cancer Vaccine Candidate Containing a Long MUC1 Glycopeptide. Chembiochem 19:121-125
Rebbeck, Timothy R (see original citation for additional authors) (2018) Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Hum Mutat 39:593-620
Msaouel, Pavlos; Opyrchal, Mateusz; Dispenzieri, Angela et al. (2018) Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects. Curr Cancer Drug Targets 18:177-187
Fasching, Peter A; Loibl, Sibylle; Hu, Chunling et al. (2018) BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study. J Clin Oncol 36:2281-2287
Rice, Megan S; Tamimi, Rulla M; Bertrand, Kimberly A et al. (2018) Does mammographic density mediate risk factor associations with breast cancer? An analysis by tumor characteristics. Breast Cancer Res Treat 170:129-141
Wang, Liewei; Ingle, James; Weinshilboum, Richard (2018) Pharmacogenomic Discovery to Function and Mechanism: Breast Cancer as a Case Study. Clin Pharmacol Ther 103:243-252
Augusto, Bianca M; Lake, Paige; Scherr, Courtney L et al. (2018) From the laboratory to the clinic: sharing BRCA VUS reclassification tools with practicing genetics professionals. J Community Genet 9:209-215
Tu, Xinyi; Kahila, Mohamed M; Zhou, Qin et al. (2018) ATR Inhibition Is a Promising Radiosensitizing Strategy for Triple-Negative Breast Cancer. Mol Cancer Ther 17:2462-2472
Athreya, Arjun P; Gaglio, Alan J; Cairns, Junmei et al. (2018) Machine Learning Helps Identify New Drug Mechanisms in Triple-Negative Breast Cancer. IEEE Trans Nanobioscience 17:251-259

Showing the most recent 10 out of 473 publications